Wenshuo Lu

USPTO Granted Patents = 10 (Patent Applications = 4)

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 85(Granted Patents)

Company Filing History:

Years Active: 2006-2016

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9440957 - Compounds and compositions for modulating EGFR Activity (2016-09-13),

2. 8859574 - Compounds and compositions as kinase inhibitors (2014-10-14),

3. 8519129 - Pyrimidine derivatives as kinase inhibitors (2013-08-27),

4. 8445505 - Pyrimidine derivatives as kinase inhibitors (2013-05-21),

5. 8440681 - 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors (2013-05-14),

6. 8399450 - Compounds and compositions as protein kinase inhibitors (2013-03-19),

7. 8153671 - Heterotetracyclic compounds as TPO mimetics (2012-04-10),

8. 7816542 - Compounds and compositions as TPO mimetics (2010-10-19),

9. 7572811 - Immunosuppressant compounds and compositions (2009-08-11),

10. 7060697 - Immunosuppressant compounds and compositions (2006-06-13),

Title: Innovations and Patents of Wenshuo Lu: A Profile

Introduction

Wenshuo Lu is an accomplished inventor based in San Diego, California, recognized for his significant contributions in the field of pharmaceuticals and biotechnology. With a total of 10 patents to his name, his work focuses on developing compounds and compositions that tackle critical health challenges.

Latest Patents

Among his notable inventions are two groundbreaking patents. The first, titled "Compounds and compositions for modulating EGFR Activity," provides a range of novel pharmaceutical compounds and compositions that are designed to modulate Epidermal Growth Factor Receptor (EGFR) activity. This innovation holds potential for treating conditions associated with abnormal or deregulated EGFR activity.

The second patent, "Compounds and compositions as kinase inhibitors," introduces new pyrimidine derivatives and their pharmaceutical applications. These compounds can be utilized for treating conditions responsive to the inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK), representing a significant advancement in targeted cancer therapies.

Career Highlights

Wenshuo Lu has made impactful strides in his career by working with leading companies in the pharmaceutical industry, including Irm LLC and Novartis AG. His experience in these organizations has greatly influenced his research and development endeavors, allowing him to translate theoretical knowledge into practical innovations.

Collaborations

Throughout his career, Wenshuo has collaborated with esteemed colleagues such as Thomas H Marsilje, III and Bei Chen. These partnerships have fostered an environment of innovation and creativity, enhancing the depth and breadth of his research and expanding the impact of his inventions.

Conclusion

Wenshuo Lu exemplifies the spirit of innovation in the pharmaceutical sector. With a focus on developing advanced compounds and compositions, his work is paving the way for new treatment modalities for conditions influenced by EGFR activity and kinase pathways. As he continues to push the boundaries of science and medicine, his contributions will undoubtedly make a lasting impact in the field.

This text is generated by artificial intelligence and may not be accurate.